Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1926 1
1927 1
1930 1
1935 1
1947 1
1953 3
1956 2
1957 3
1958 2
1960 1
1961 1
1962 2
1963 8
1964 7
1965 18
1966 9
1967 24
1968 15
1969 30
1970 28
1971 39
1972 39
1973 47
1974 83
1975 278
1976 276
1977 272
1978 296
1979 335
1980 393
1981 439
1982 498
1983 643
1984 725
1985 802
1986 863
1987 1000
1988 1139
1989 1504
1990 1818
1991 2074
1992 2420
1993 2807
1994 3061
1995 3343
1996 3671
1997 4103
1998 4714
1999 5232
2000 6252
2001 7024
2002 7671
2003 8555
2004 9537
2005 10577
2006 11651
2007 12130
2008 13069
2009 14088
2010 15641
2011 17090
2012 18037
2013 19190
2014 19623
2015 19738
2016 19396
2017 19747
2018 20111
2019 20321
2020 20581
2021 10077
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

330,253 results
Results by year
Filters applied: . Clear all
Page 1
Showing results for many genetic
Search for Jan Geletič instead (3 results)
Recent developments in genetic/genomic medicine.
Horton RH, Lucassen AM. Horton RH, et al. Clin Sci (Lond). 2019 Mar 5;133(5):697-708. doi: 10.1042/CS20180436. Print 2019 Mar 15. Clin Sci (Lond). 2019. PMID: 30837331 Free PMC article. Review.
Advances in genetic technology are having a major impact in the clinic, and mean that many perceptions of the role and scope of genetic testing are having to change. ...The landscape of treatment options for genetic conditions is shifting, which has ev …
Advances in genetic technology are having a major impact in the clinic, and mean that many perceptions of the role and scope o …
Genetics of Inflammatory Bowel Diseases.
McGovern DP, Kugathasan S, Cho JH. McGovern DP, et al. Gastroenterology. 2015 Oct;149(5):1163-1176.e2. doi: 10.1053/j.gastro.2015.08.001. Epub 2015 Aug 7. Gastroenterology. 2015. PMID: 26255561 Free PMC article. Review.
Importantly, the large majority of GWAS-associated loci involve noncoding variation, many of which modulate levels of gene expression. Recent expression quantitative trait loci (eQTL) studies have established that the expression of most human genes is regulated by noncodin …
Importantly, the large majority of GWAS-associated loci involve noncoding variation, many of which modulate levels of gene expression …
Gene therapy on the move.
Kaufmann KB, Büning H, Galy A, Schambach A, Grez M. Kaufmann KB, et al. EMBO Mol Med. 2013 Nov;5(11):1642-61. doi: 10.1002/emmm.201202287. Epub 2013 Sep 17. EMBO Mol Med. 2013. PMID: 24106209 Free PMC article. Review.
The first gene therapy clinical trials were initiated more than two decades ago. In the early days, gene therapy shared the fate of many experimental medicine approaches and was impeded by the occurrence of severe side effects in a few treated patients. ...
The first gene therapy clinical trials were initiated more than two decades ago. In the early days, gene therapy shared the fa …
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases.
Rupaimoole R, Slack FJ. Rupaimoole R, et al. Nat Rev Drug Discov. 2017 Mar;16(3):203-222. doi: 10.1038/nrd.2016.246. Epub 2017 Feb 17. Nat Rev Drug Discov. 2017. PMID: 28209991 Review.
Functional studies have confirmed that miRNA dysregulation is causal in many cases of cancer, with miRNAs acting as tumour suppressors or oncogenes (oncomiRs), and miRNA mimics and molecules targeted at miRNAs (antimiRs) have shown promise in preclinical development. ...
Functional studies have confirmed that miRNA dysregulation is causal in many cases of cancer, with miRNAs acting as tumour suppressor …
Targeting epigenetics for cancer therapy.
Park JW, Han JW. Park JW, et al. Arch Pharm Res. 2019 Feb;42(2):159-170. doi: 10.1007/s12272-019-01126-z. Epub 2019 Feb 26. Arch Pharm Res. 2019. PMID: 30806885 Free PMC article. Review.
It was once believed that cancer is caused by a progressive series of genetic aberrations, and certain mutations of genes, including oncogenes and tumor suppressor genes, have been identified as the cause of cancer. However, piling evidence suggests that epigenetic modific …
It was once believed that cancer is caused by a progressive series of genetic aberrations, and certain mutations of genes, including …
AAV-based gene therapies for the muscular dystrophies.
Crudele JM, Chamberlain JS. Crudele JM, et al. Hum Mol Genet. 2019 Oct 1;28(R1):R102-R107. doi: 10.1093/hmg/ddz128. Hum Mol Genet. 2019. PMID: 31238336 Free PMC article. Review.
Muscular dystrophy (MD) is a group of progressive genetic diseases affecting the musculature that are characterized by inflammatory infiltrates, necrosis and connective tissue and fat replacement of the affected muscles. Unfortunately, treatments do not exist for the vast …
Muscular dystrophy (MD) is a group of progressive genetic diseases affecting the musculature that are characterized by inflammatory i …
Emerging therapeutic targets for neurofibromatosis type 1.
Walker JA, Upadhyaya M. Walker JA, et al. Expert Opin Ther Targets. 2018 May;22(5):419-437. doi: 10.1080/14728222.2018.1465931. Epub 2018 May 7. Expert Opin Ther Targets. 2018. PMID: 29667529 Free PMC article. Review.
The NF1 gene encodes neurofibromin, which functions as a negative regulator of RAS. NF1 is a chronic multisystem disorder affecting many different tissues. Due to cell-specific complexities of RAS signaling, therapeutic approaches for NF1 will likely have to focus on a par …
The NF1 gene encodes neurofibromin, which functions as a negative regulator of RAS. NF1 is a chronic multisystem disorder affecting many
Molecular genetics and emerging therapies for retinitis pigmentosa: Basic research and clinical perspectives.
Dias MF, Joo K, Kemp JA, Fialho SL, da Silva Cunha A Jr, Woo SJ, Kwon YJ. Dias MF, et al. Prog Retin Eye Res. 2018 Mar;63:107-131. doi: 10.1016/j.preteyeres.2017.10.004. Epub 2017 Oct 31. Prog Retin Eye Res. 2018. PMID: 29097191 Review.
Current therapies for RP in ongoing or completed clinical trials include gene therapy, cell therapy, and retinal prostheses. Gene therapy, a strategy to correct the genetic defects using viral or non-viral vectors, has the potential to achieve definiti …
Current therapies for RP in ongoing or completed clinical trials include gene therapy, cell therapy, and retinal prostheses. G …
Gene therapy for neurological disorders.
Choong CJ, Baba K, Mochizuki H. Choong CJ, et al. Expert Opin Biol Ther. 2016;16(2):143-59. doi: 10.1517/14712598.2016.1114096. Epub 2015 Dec 5. Expert Opin Biol Ther. 2016. PMID: 26642082 Review.
INTRODUCTION: Many nervous system disorders are minimally responsive to existing treatments but they are potential candidates for gene therapy, an approach that can correct the genetic abnormalities contributing to its pathogenesis at molecular level. ...AREA …
INTRODUCTION: Many nervous system disorders are minimally responsive to existing treatments but they are potential candidates for gen …
AAV: An Overview of Unanswered Questions.
Berns KI, Muzyczka N. Berns KI, et al. Hum Gene Ther. 2017 Apr;28(4):308-313. doi: 10.1089/hum.2017.048. Hum Gene Ther. 2017. PMID: 28335618 Free PMC article. Review.
By now, there is a fairly good idea of the dimensions of what would be useful to know to employ AAV optimally as a vector, but there are still many unanswered questions within the system. As with all biological systems, each good experiment raises further questions to answ …
By now, there is a fairly good idea of the dimensions of what would be useful to know to employ AAV optimally as a vector, but there are sti …
330,253 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page